What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
Nonalcoholic steatohepatitis (NASH) can progress to cirrhosis and its complications, including hepatocellular carcinoma. Given that the majority of patients with NASH are asymptomatic, developing screening strategies to identify those individuals at risk for progressive NASH remains a highly unmet n...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2021-11-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1814 |
| _version_ | 1811174036612317184 |
|---|---|
| author | Naim Alkhouri Monica Tincopa Rohit Loomba Stephen A. Harrison |
| author_facet | Naim Alkhouri Monica Tincopa Rohit Loomba Stephen A. Harrison |
| author_sort | Naim Alkhouri |
| collection | DOAJ |
| description | Nonalcoholic steatohepatitis (NASH) can progress to cirrhosis and its complications, including hepatocellular carcinoma. Given that the majority of patients with NASH are asymptomatic, developing screening strategies to identify those individuals at risk for progressive NASH remains a highly unmet need. Furthermore, noninvasive tests that accurately predict disease progression as part of the natural history of NASH or regression in response to treatment are urgently needed to decrease the reliance on repeat liver biopsies. To date, there are no US Food and Drug Administration (FDA)‐approved medications for NASH that can resolve steatohepatitis and lead to fibrosis regression. The lack of FDA‐approved therapy has led to apathy in diagnosis and referral for specialty care. However, several therapeutic agents are rapidly progressing through the different phases of clinical trials with several already in phase 3 programs. In this review, we provide a summary of recent developments in NASH diagnostics and therapeutics that are likely to shape the future management of this underdiagnosed and undertreated disease. |
| first_indexed | 2024-04-10T17:56:36Z |
| format | Article |
| id | doaj.art-c49d6b2d8bc244fcb0ba73a990d623ed |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-04-10T17:56:36Z |
| publishDate | 2021-11-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-c49d6b2d8bc244fcb0ba73a990d623ed2023-02-02T17:47:17ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2021-11-015111810182310.1002/hep4.1814What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?Naim Alkhouri0Monica Tincopa1Rohit Loomba2Stephen A. Harrison3Arizona Liver Health Chandler AZ USAWell Consulting Los Angeles CA USANAFLD Research Center University of California at San Diego La Jolla CA USARadcliffe Department of Medicine University of Oxford Oxford United KingdomNonalcoholic steatohepatitis (NASH) can progress to cirrhosis and its complications, including hepatocellular carcinoma. Given that the majority of patients with NASH are asymptomatic, developing screening strategies to identify those individuals at risk for progressive NASH remains a highly unmet need. Furthermore, noninvasive tests that accurately predict disease progression as part of the natural history of NASH or regression in response to treatment are urgently needed to decrease the reliance on repeat liver biopsies. To date, there are no US Food and Drug Administration (FDA)‐approved medications for NASH that can resolve steatohepatitis and lead to fibrosis regression. The lack of FDA‐approved therapy has led to apathy in diagnosis and referral for specialty care. However, several therapeutic agents are rapidly progressing through the different phases of clinical trials with several already in phase 3 programs. In this review, we provide a summary of recent developments in NASH diagnostics and therapeutics that are likely to shape the future management of this underdiagnosed and undertreated disease.https://doi.org/10.1002/hep4.1814 |
| spellingShingle | Naim Alkhouri Monica Tincopa Rohit Loomba Stephen A. Harrison What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Hepatology Communications |
| title | What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? |
| title_full | What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? |
| title_fullStr | What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? |
| title_full_unstemmed | What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? |
| title_short | What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? |
| title_sort | what does the future hold for patients with nonalcoholic steatohepatitis diagnostic strategies and treatment options in 2021 and beyond |
| url | https://doi.org/10.1002/hep4.1814 |
| work_keys_str_mv | AT naimalkhouri whatdoesthefutureholdforpatientswithnonalcoholicsteatohepatitisdiagnosticstrategiesandtreatmentoptionsin2021andbeyond AT monicatincopa whatdoesthefutureholdforpatientswithnonalcoholicsteatohepatitisdiagnosticstrategiesandtreatmentoptionsin2021andbeyond AT rohitloomba whatdoesthefutureholdforpatientswithnonalcoholicsteatohepatitisdiagnosticstrategiesandtreatmentoptionsin2021andbeyond AT stephenaharrison whatdoesthefutureholdforpatientswithnonalcoholicsteatohepatitisdiagnosticstrategiesandtreatmentoptionsin2021andbeyond |